How to buy Provention Bio stock | $16.53

Provention Bio, Inc is a biotechnology business based in the US. Provention Bio shares (PRVB) are listed on the NASDAQ and all prices are listed in US Dollars. Provention Bio employs 19 staff and has a market cap (total outstanding shares value) of USD$885.2 million.

How to buy shares in Provention Bio

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Provention Bio. Find the stock by name or ticker symbol: PRVB. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Provention Bio reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$16.53, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Provention Bio, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Provention Bio. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Provention Bio share price

Use our graph to track the performance of PRVB stocks over time.

Provention Bio shares at a glance

• Key figures

Information last updated 2020-12-03.

Latest market close	USD$16.53
52-week range	USD$4.72 - USD$18.5
50-day moving average	USD$13.7697
200-day moving average	USD$13.406
Wall St. target price	USD$28.29
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.943

Buy Provention Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Provention Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Provention Bio, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Provention Bio price performance over time

Historical closes compared with the close of $16.53 from 2020-12-09

1 week (2021-01-08)	-6.08%
1 month (2020-12-16)	-10.02%
3 months (2020-10-15)	23.82%
6 months (2020-07-15)	30.98%

1 year (2020-01-15)	7.48%
2 years (2019-01-15)	661.75%
3 years (2018-01-15)	N/A
5 years (2016-01-15)	N/A

Provention Bio financials

Gross profit TTM	USD$0
Return on assets TTM	-39.26%
Return on equity TTM	-67.5%
Profit margin	0%
Book value	$2.397
Market capitalisation	USD$885.2 million

TTM: trailing 12 months

Shorting Provention Bio shares

There are currently 3.5 million Provention Bio shares held short by investors – that's known as Provention Bio's "short interest". This figure is 4.1% down from 3.6 million last month.

There are a few different ways that this level of interest in shorting Provention Bio shares can be evaluated.

Provention Bio's "short interest ratio" (SIR)

Provention Bio's "short interest ratio" (SIR) is the quantity of Provention Bio shares currently shorted divided by the average quantity of Provention Bio shares traded daily (recently around 453912.94117647). Provention Bio's SIR currently stands at 7.65. In other words for every 100,000 Provention Bio shares traded daily on the market, roughly 7650 shares are currently held short.

However Provention Bio's short interest can also be evaluated against the total number of Provention Bio shares, or, against the total number of tradable Provention Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Provention Bio's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Provention Bio shares in existence, roughly 60 shares are currently held short) or 0.0678% of the tradable shares (for every 100,000 tradable Provention Bio shares, roughly 68 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Provention Bio.

Find out more about how you can short Provention Bio stock.

Provention Bio share dividends

We're not expecting Provention Bio to pay a dividend over the next 12 months.

Provention Bio share price volatility

Over the last 12 months, Provention Bio's shares have ranged in value from as little as $4.72 up to $18.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Provention Bio's is 3.554. This would suggest that Provention Bio's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Provention Bio overview

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase 1b clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.

Frequently asked questions

• What percentage of Provention Bio is owned by insiders or institutions?

  Currently 18.252% of Provention Bio shares are held by insiders and 42.841% by institutions.

• How many people work for Provention Bio?

  Latest data suggests 19 work at Provention Bio.

• When does the fiscal year end for Provention Bio?

  Provention Bio's fiscal year ends in December.

• Where is Provention Bio based?

  Provention Bio's address is: PO Box 666, Oldwick, NJ, United States, 08858

• What is Provention Bio's ISIN number?

  Provention Bio's international securities identification number is: US74374N1028

• What is Provention Bio's CUSIP number?

  Provention Bio's Committee on Uniform Securities Identification Procedures number is: 74374N102